Lupin Limited, a leading pharmaceutical company based in India, received World Health Organization (WHO) prequalification for its 200mg pretomanid tablet. This achievement adds another manufacturer to the market for a critical component of WHO-endorsed six-month drug-resistant TB treatments. Having multiple producers strengthens the global supply of pretomanid, ensures consistent quality, and drives competition that helps further lower costs.

PeerLINC’s G-TEC brought together experts from 18 countries to review complex DR-TB cases from the Philippines and India, demonstrating how collective expertise can guide safer and more effective treatment decisions.

PeerLINC Knowledge Hub joined global and national TB leaders at the 31st Philippine Coalition Against Tuberculosis (PhilCAT) Annual Convention, held August 14 to 15. A key focus of the convention was accelerating access to new WHO-recommended regimens for drug-resistant TB (DR-TB).

As part of India’s accelerated rollout of the WHO-recommended six-month, all-oral BPaLM/BPaL regimen for drug-resistant tuberculosis (DR-TB), a total of 136 TB physicians from both public and private sectors gathered for high-level experience-sharing workshops in New Delhi and Mumbai.

PeerLINC concluded a three-day online training on new regimens for drug-resistant tuberculosis and other special TB topics. Participants included National TB Program (NTP) managers across Mongolia. Knowledge areas covered included updates to WHO-recommended regimens, including BPaL/M, managing adverse drug reactions, DR-TB in pregnancy, TB-diabetes comorbidity, and modified regimens for drug-susceptible TB in special cases.

PeerLINC recently welcomed a delegation from Bangladesh’s National Tuberculosis Program (NTP) to a weeklong capacity-building program aimed at accelerating the country’s transition to shorter, safer treatment regimens for drug-resistant tuberculosis (DR-TB). The training combined interactive lectures, workshops, and field visits across Metro Manila to offer a comprehensive view of implementing the WHO-recommended six-month BPaLM/BPaL regimens.

The Global Technical Expert Council (GTEC), an has announced a significant expansion, welcoming 22 new members from several additional countries.

In a significant step toward improving drug-resistant tuberculosis (DR-TB) care, the PeerLINC Knowledge Hub conducted an intensive training from February 3-7, 2025, equipping national and regional personnel of Disease Prevention and Control Bureau (DPCB) of DOH of the Philippines with the knowledge and skills to implement the BPaL/M treatment regimen.

In PeerLINC’s first year of operations it empowered eight countries to accelerate the adoption of shorter, safer, and more effective DR-TB treatments, improving lives and strengthening healthcare systems worldwide.